Tag: Osteopenia

While many people associate FDA approval with new drugs, Osteoboost is not a medication but a wearable medical device. In early 2024, the U.S. Food and Drug Administration granted it clearance through the De Novo pathway, a distinct regulatory process from that for pharmacological agents.

According to the American College of Rheumatology, bisphosphonates are often the first line of defense to slow bone loss in individuals with low bone density. Answering what is the oral treatment for osteopenia involves understanding these medications, along with the critical role of supplements and lifestyle adjustments.